Paul Algate

Paul is passionate about discovering and translating innovative science into transforming medicines for patients.  He has over 20 years of research and development experience discovering and developing antibody therapeutics for oncology, inflammation and infectious disease.  As former Director of Biology at Theraclone/OncoResponse, Paul led teams responsible for the discovery and characterization of rare antibodies from the natural human immune repertoire using I-STAR™ technology, including those from Elite Cancer Responders to Checkpoint Inhibition.  Before joining Theraclone, he had a leadership role at Trubion Pharmaceuticals/Emergent Biosolutions where he developed novel mono- and bi-specific (SMIP/Scorpion/ADAPTIR™) protein therapeutics from discovery through Phase II clinical studies.  In his early career at Corixa Corporation/GSK-Biologics, he discovered, characterized and validated vaccine and antibody therapeutic targets.

Paul was a Research Fellow at the Fred Hutchinson Cancer Research Center and received his Ph.D. from the Department of Microbiology and Immunology at the Brody School of Medicine, East Carolina University.  He is an inventor and author on numerous patents and patent applications and his collaborative work has been published in scientific papers, books and review articles.